ClinicalTrials.Veeva

Menu

Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG

R

Robert Ritch, MD, LLC.

Status

Unknown

Conditions

Normal Tension Glaucoma

Treatments

Other: Placebo
Dietary Supplement: Gingko Baloba

Study type

Interventional

Funder types

Other

Identifiers

NCT03761992
NFC Gingko

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of Ginkgo biloba extract (GBE) on the number of blood vessels in the back of the eye as well as the amount of blood flow at the nailfold(where the fingernail meets the skin) of the 4th finger in the hand.This finger, along with the 5th finger, has the most transparent skin, which makes imaging a little easier. GBE is an over-the-counter pill, made from a natural powder taken from the Gingko (Maidenhair) tree, that is widely used. A technique called Optical Coherence Tomography Angiography (OCTA),will be used to measure the small blood vessels at the back of the eye, the macula (the area of sharpest vision), and the optic disc (the point at which the nerve fibers from the retina enter to form the optic nerve, which transmits visual impulses to the brain).

Full description

GBE has been reported to improve blood flow to the brain, eye, and extremeties(hands, feet,etc.). .As with most supplements, GBE is neither regulated nor FDA approved.

A technique called Optical Coherence Tomography Angiography (OCTA),will be used to measure the small blood vessels at the back of the eye, the macula (the area of sharpest vision), and the optic disc (the point at which the nerve fibers from the retina enter to form the optic nerve, which transmits visual impulses to the brain). This technique uses a camera, capable of imaging the smallest vessels, so that their density (number) can be calculated by a computer. This is being done to determine if there is disease causing increasing loss of these vessels. The imaging is done by a widely used camera which does not contact the eye. It simply uses visible light to measure the amount of blood vessels present in a determined area in the back of the eye. Blood flow at the 4th finger nailfold (nailfold capillaroscopy; NFC) is a standard technique, especially in rheumatology, performed by using a commercially available light microscope which glides over the base of the fingernail and can image the tiny capillaries in the nailfold. These images are recorded as videos from which the blood flow can be analyzed by freely available software for the purpose of quantitative measurements (amount of blood flow and blood flow velocity).

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female of any race, at least 18 years of age

  • Has provided verbal and written informed consent.
  • Able and willing to follow instructions, including participation in all study assessments and visits.
  • Eyes with NTG will be enrolled.
  • Glaucoma severity will be graded using the WHO (World Health Organization)staging system.

NTG diagnosis will be based on the following:

  1. Glaucomatous optic disc on slit-lamp biomicroscopy defined as cup-to-disc ratio greater than 0.7, inter-eye asymmetry in cup-to-disc ration greater than 0.2 or neuroretinal rim notching, focal thinning, disc hemorrhage or vertical elongation of optic disc.

  2. Glaucomatous visual field defects on at least three reliable visual field examinations as measured by a glaucoma hemifield test (GHT) result outside normal limits and/or the appearance of at least three consecutive test points on the pattern deviation plot with p<1% and at least one at p<0.05%, not including points on the edge of the field.

  3. NTG will be defined as those subjects with a history of untreated peak IOP ≤21 mmHg.

    • Both eyes will be enrolled

Exclusion criteria

  • Best-corrected visual acuity less than 20/40
  • Age younger than 18 years or older than 85 years
  • Refractive error greater than +3.00 diopters (D) or less than -7.00 diopters (D)
  • Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation
  • Any other diseases that may cause visual field loss or optic disc abnormalities
  • Inability to perform reliably on automated visual field testing.
  • Subjects taking any GBE product will be washed out for 2 weeks prior to enrollment.
  • Diabetes.
  • Seizure disorder.
  • Taking any drugs that may interact with GBE (as listed).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

40 participants in 2 patient groups, including a placebo group

Gingko Biloba Extract
Active Comparator group
Description:
Gingko Biloba Extract 240 mg.
Treatment:
Dietary Supplement: Gingko Baloba
Placebo
Placebo Comparator group
Description:
Placebo Pill
Treatment:
Other: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Luis Silva MD, MD; Robert Ritch, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems